Ensysce Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ensysce Biosciences, Inc. on April 1, 2025. The report addresses an administrative correction regarding the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was originally filed on March 10, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to correct a disclosure omission in a prior filing and does not contain new financial data.
Material Changes
There are no material changes to financial results or other disclosures. The filing corrects an inadvertent omission in the "Consent of Independent Registered Public Accounting Firm" (Exhibit 23.1) attached to the Form 10-K. The original consent failed to reference Registration Statements No. 333-275456 and No. 333-276537 on Form S-3. A revised consent dated April 1, 2025, has been filed to rectify this.
Guidance, Outlook, and Risks
The filing contains no new management commentary, guidance, outlook, or discussion of risks and contingencies. The company explicitly states that the revised consent does not change any previously reported financial results or other disclosure contained in the Form 10-K.
Investor Verification Checklist
- Verify the corrected Exhibit 23.1 (Consent of Moss Adams LLP) is attached to this 8-K.
- Confirm that the original Form 10-K for the fiscal year ended December 31, 2024, remains the primary source for financial performance data.
- Note that the correction is administrative and does not alter the company's financial standing or operational status.